MedPath

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

Clinical Trials

499

Active:227
Completed:208

Trial Phases

5 Phases

Phase 1:189
Phase 2:56
Phase 3:145
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (409 trials with phase data)• Click on a phase to view related trials

Phase 1
189 (46.2%)
Phase 3
145 (35.5%)
Phase 2
56 (13.7%)
Phase 4
16 (3.9%)
Not Applicable
2 (0.5%)
phase_2_3
1 (0.2%)

A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety

Phase 3
Recruiting
Conditions
ADHD
Anxiety
Generalized Anxiety
Social Anxiety Disorder
Interventions
Other: Placebo
First Posted Date
2025-05-15
Last Posted Date
2025-05-31
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
308
Registration Number
NCT06973577
Locations
🇺🇸

Clinical Research Site #017 - Harmonex Neuroscience Research, Dothan, Alabama, United States

🇺🇸

Clinical Research Site #011 - NRC Research Institute, Orange, California, United States

🇺🇸

Clinical Research Site #005 - Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States

and more 5 locations

A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)

Phase 3
Not yet recruiting
Conditions
Phenylketonuria
Interventions
Drug: JNT-517 Tablet
First Posted Date
2025-05-14
Last Posted Date
2025-06-03
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
120
Registration Number
NCT06971731

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

Phase 2
Recruiting
Conditions
Sjogren Disease
Interventions
First Posted Date
2025-04-15
Last Posted Date
2025-07-10
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
80
Registration Number
NCT06928142
Locations
🇺🇸

Medvin Clinical Research - Riverside, Riverside, California, United States

🇺🇸

Medvin Clinical Research - Tujunga, Tujunga, California, United States

🇺🇸

Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States

and more 15 locations

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Phase 3
Recruiting
Conditions
Schizophrenia
Interventions
Other: Placebo
First Posted Date
2025-03-25
Last Posted Date
2025-05-18
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
522
Registration Number
NCT06894212
Locations
🇺🇸

Pillar Clinical Research LLC - Bentonville Site # 145, Bentonville, Arkansas, United States

🇺🇸

Pillar Clinical Research (Little Rock AR) Site #153, Little Rock, Arkansas, United States

🇺🇸

Woodland International Research Group Site #141, Little Rock, Arkansas, United States

and more 31 locations

A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure

Phase 2
Not yet recruiting
Conditions
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2025-03-25
Last Posted Date
2025-03-27
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
264
Registration Number
NCT06795399
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 51
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath